Quality detection method of nalmefene hydrochloride injection

By using gradient elution procedures and optimized chromatographic conditions in the HPLC detection method of Namefen Hydrochloride injection, the problems of inaccurate and inefficient impurities detection in the prior art were solved, and impurities in Namefen Hydrochloride injection were realized The accuracy of the detection method and the durability of the detection method ensure the safety of the quality of the drug.

CN119086792APending Publication Date: 2024-12-06SICHUAN JIANLIN PHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411592132.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-11-08
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing quality detection methods for nalmefen hydrochloride injection have problems such as inaccurate detection of impurities, low efficiency and prone to blockage of liquid phase systems, especially during long-term injection, which leads to inaccurate results and reduced detection efficiency.

Method used

By using HPLC method combined with gradient elution procedure, optimized chromatographic column and mobile phase composition, a quality detection method for naltrexone hydrochloride and doublenamifen injection is provided, including Specific chromatographic conditions and detection steps ensure the accuracy and durability of the detection.

Benefits of technology

Accurate detection of impurities in Namefen hydrochloride injection, improve the durability and efficiency of the detection, ensure the scientificity of the testing methods of the manufacturer and the safety of clinical drugs, and solve the relevant impurities and unknown degradation impurities determined by statutory standards. Interference issues.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119086792A_ABST
    Figure CN119086792A_ABST
Patent Text Reader

Abstract

The invention provides a quality detection method of a nalmefene hydrochloride injection, and belongs to the field of medicine detection. According to the quality detection method of the nalmefene hydrochloride injection, impurities in the nalmefene hydrochloride injection are detected through an HPLC (High Performance Liquid Chromatography) method, the impurities comprise one or a mixture of more than two of an impurity I and an impurity II, the impurity I is naltrexone hydrochloride, and the impurity II is bisnalmefene. The HPLC detection method for the related substances in the nalmefene hydrochloride injection, which has high specificity, is screened and determined, so that the related substances in the nalmefene hydrochloride injection can be accurately and exclusively detected, and a reasonable and scientific detection method is provided for release of a nalmefene hydrochloride injection manufacturer; a practical basis is provided for improving the quality standard of related substances of the nalmefene hydrochloride injection, and a guarantee is provided for clinical medication safety.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a quality detection method for nalmefene hydrochloride injection, and belongs to the field of drug detection. Background Art

[0002] Nalmefene hydrochloride is a receptor antagonist, approved by the FDA in 1995, and is used clinically to treat reversal of opioid-induced respiratory depression, etc. Depending on the dosage, it can also be used for morphine antagonism or addiction. According to the clinical use characteristics of nalmefene hydrochloride, the nalmefene hydrochloride currently on the market is injection, and the administration method is intravenous injection. The general specifications are 1ml: 0.1mg, 2ml: 2mg. Its structural formula is as follows:

[0003] According to the chemical structure of nalmefene hydrochloride, there is an enol structure in the main skeleton structure of nalmefene, that is, there are both hydroxyl groups and carbon-carbon double bonds on the same carbon. This type of structure is extremely unstable and is prone to enol structure interconversion or free radical reactions caused by enol structure interconversion. Through investigation, nalmefene hydrochloride will undergo free radical reactions and degrade under the influence of light, oxidation and metal ions.

[0004] At present, the synthesis process of nalmefene hydrochloride mostly adopts a one-step reaction synthesis method of naltrexone hydrochloride and methyltriphenylphosphonium bromide. During the reaction, in order to avoid the introduction of metal ions causing a large amount of impurities and a decrease in yield, a glass reactor is generally used for the synthesis reaction.

[0005] Injections do not have drug absorption and penetration and directly enter the human body to take effect. Therefore, general companies will fully study the interaction between the inner packaging material and the drug solution before applying for drug registration and listing to relevant national agencies. The main purpose is to study the changes in the inner surface of the packaging material during the continuous contact between the drug and the packaging material and the leaching effect of the drug solution on unknown substances (such as metal ions) in the packaging material. At present, the inner packaging material of injections is generally medium borosilicate glass ampoules or vials. In order to reduce the risk of clinical drug use and control the quality of drugs, the State Food and Drug Administration basically no longer approves low borosilicate glass ampoules as inner packaging materials for injections. According to the rapid effect of nalmefene hydrochloride in clinical treatment, nalmefene hydrochloride is used for intravenous injection. The finished drug preparation is generally a small-volume water injection, and the inner packaging material is a low (medium) borosilicate glass ampoule or vial. For nalmefene hydrochloride injection, the main problem is that the leached metal ions will continue to cause the degradation of nalmefene hydrochloride, thereby causing the drug to deteriorate and become ineffective. Excessive impurities in clinical practice may also cause serious side effects.

[0006] The possible impurity pathways in nalmefene hydrochloride injection are mainly: ① Naltrexone hydrochloride brought in by the starting materials that has not been completely removed; ② Other impurities generated by high temperature, light, oxygen or metal ions during production, transportation and storage, such as dinalmefene (a typical degradation product of nalmefene free radical reaction). The impurity structure of nalmefene hydrochloride raw material in the 2020 edition of the Chinese Pharmacopoeia is as follows:

[0007] Impurity I: Naltrexone hydrochloride structure

[0008] Impurity II: Binalmefene structure Based on the requirements of quality control, the raw material of nalmefene hydrochloride is included in the relevant quality standards in the Chinese Pharmacopoeia. No relevant standards have been found in other countries and regions to control nalmefene hydrochloride injection. The main target of the Chinese Pharmacopoeia for the control of related substances in nalmefene hydrochloride injection is dinalmefene, but other unknown impurities are still included. Yuan Xinya, et al., HPLC determination of related substances in nalmefene hydrochloride injection, Chinese Journal of Pharmaceutical Industry, 2010, 41(3), Zhong Wu, et al., HPLC determination of the content of nalmefene hydrochloride and its related substances, Chinese Journal of New Drugs, Vol. 15, No. 11, 2006, disclosed that the quality detection method of nalmefene hydrochloride in the pharmacopoeia was used to detect naltrexone hydrochloride and dinalmefene. The method used was isocratic elution HPLC-VWD method. Although this method is simple to operate and basically meets the requirements of relevant management agencies, it also has corresponding problems, mainly the following points: ① Through the synthesis process of nalmefene hydrochloride, nalmefene hydrochloride is prepared by a one-step synthesis reaction of naltrexone hydrochloride and triphenylmethylphosphonium bromide. Analysis of the process shows that there may be many by-product impurities. ② Through the forced degradation experiment of nalmefene hydrochloride (acid, alkali, oxygen and other conditions), there are many possible unknown degradation impurities. ③ The HPLC method itself has a high salt concentration (the elution mobile phase is: 0.05mol / L sodium dihydrogen phosphate solution (take 7.8g of sodium dihydrogen phosphate, add 900ml of water to dissolve, add 2.0ml of triethylamine, adjust the pH value to 4.2 with phosphoric acid, and dilute with water to 1000ml) - acetonitrile (80:20)). In the actual research process, the method has poor durability. When injected for a long time, it is easy to cause the liquid phase system to be blocked, resulting in inaccurate results and reduced efficiency. Summary of the invention

[0009] The technical solution of the present invention is to provide a quality detection method for nalmefene hydrochloride injection.

[0010] The present invention provides a quality detection method for nalmefene hydrochloride injection, which detects impurities in nalmefene hydrochloride injection by HPLC, wherein the impurities include one or a mixture of two or more of impurities I and II, wherein the impurity I is naltrexone hydrochloride, and the impurity II is bisnalmefene; The chromatographic conditions are: The chromatographic column was Kromasil C18 4.6 × 250 mm, 5 μm; Mobile phase A was acetonitrile-phosphate buffer, mobile phase B was acetonitrile-water solution, and the gradient elution program was:

[0011] Flow rate: 0.9~1.1ml / min; Column temperature is 25~35℃; The injection volume is 20~50μl; The detection wavelength is 205~215nm.

[0012] Further preferably, the volume ratio of the acetonitrile-phosphate buffer is 3:97, and the phosphate buffer is prepared by diluting 3.12 g of sodium dihydrogen phosphate and 2.0 ml of triethylamine with water to 1000 ml, and adjusting the pH to 4.2 with phosphoric acid; the volume ratio of acetonitrile to water in the acetonitrile-water solution is 97:3.

[0013] The flow rate is 1.0 ml / min; the column temperature is 35° C.; the injection volume is 20 μl; and the detection wavelength is 210 nm.

[0014] The quality detection method of nalmefene hydrochloride injection of the present invention comprises the following steps: a. Take the test solution: nalmefene hydrochloride injection; b. Preparation of control solution: Take 1 ml of the test solution and dilute it to 100 ml with 0.9% sodium chloride solution; c. Impurity reference substance: Take 2 mg of impurity I and 5 mg of impurity II, dissolve them in the same 100 ml volumetric flask, add 2 / 3 of the total volume of acetonitrile, and dilute with water to the fixed volume; accurately measure 1 ml of the above solution, add 0.9% sodium chloride solution to dilute to 100 ml, and obtain; d. Use HPLC to detect impurities in the test sample.

[0015] Among them, the retention times of the impurities detected in step d are: impurity I: 6.412min-8.623min, impurity II: 22.468-23.546min; The contents of impurities are respectively: impurity I: 0.144-0.157% w / w, impurity II: 0.291-0.316% w / w.

[0016] The beneficial effects of the present invention are: The present invention optimizes the same system on the basis of the statutory standards, such as converting isocratic elution to gradient elution, optimizing the chromatographic column, and screening the salt concentration to determine a HPLC detection method for related substances in nalmefene hydrochloride injection with considerable specificity. Through the investigation of known impurity specificity, unknown impurity specificity, sensitivity, linearity, repeatability and other experimental investigations, accurate and exclusive detection of related substances in nalmefene hydrochloride injection is achieved. The detection method of the present invention is highly durable and will not cause clogging of the liquid phase system during long-term sampling. It provides a reasonable and scientific detection method for the release of nalmefene hydrochloride injection manufacturers, provides a realistic basis for improving the quality standards of related substances in nalmefene hydrochloride injection, and provides a guarantee for the safety of clinical medication. In addition, the method described in the present invention not only solves the problem of interference in the determination of related impurities in the statutory standards, but also further solves the possible interference in the determination of unknown degradation impurities. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 The blank solution chromatogram is a specificity test in the examples; Figure 2 This is a chromatogram of the blank auxiliary material solution for specificity investigation in the examples; Figure 3 The chromatogram of the impurity spiked solution for specificity investigation in the embodiment (wherein, the retention time of nalmefene is 16.030min, the retention time of impurity I is 6.412min, the retention time of impurity II is 22.468min, and the retention time of the unknown impurity is 7.491min); Figure 4 It is the linear equation diagram of nalmefene in the embodiment; Figure 5 It is the linear equation diagram of impurity I in the embodiment; Figure 6 It is the linear equation diagram of impurity II in the embodiment; Figure 7 This is the chromatogram of the test solution spiked with impurities in Test Example 1; Figure 8 The chromatogram of the test solution spiked with impurities in Test Example 2 (wherein the retention time of nalmefene is 19.061 min, the retention time of impurity I is 11.031 min, the retention time of impurity II is 25.758 min, and the retention time of the unknown impurity is 16.733); Fig. 9 The chromatogram of the impurity spiked test solution in gradient 2 condition in Test Example 3 (wherein the retention time of nalmefene is 14.466, the retention time of impurity I is: 7.820, the retention time of impurity II is 21.121, and the retention time of unknown impurities is 6.923min and 12.331min); Fig.10The chromatogram of the impurity spiked test solution under gradient 3 conditions in Test Example 3 (wherein the retention time of nalmefene is 16.209, the retention time of impurity I is 7.716, the retention time of impurity II is 23.587, and the retention times of unknown impurities are 6.560min and 13.699min); Fig.11 The chromatogram of the impurity spiked test solution in gradient 4 condition in Test Example 3 (wherein the retention time of nalmefene is 15.645, the retention time of impurity I is 8.383, the retention time of impurity II is 19.717, and the retention times of unknown impurities are 7.015min and 13.851min); Fig.12 The chromatogram of the impurity spiked test solution under gradient 5 conditions in Test Example 3 (wherein the retention time of nalmefene is 16.184, the retention time of impurity I is 7.705, the retention time of impurity II is 23.546, and the retention times of unknown impurities are 6.556min and 13.678min); Fig.13 The chromatogram of the test solution spiked with impurities in Test Example 4 (wherein the retention time of nalmefene is 17.314, the retention time of impurity I is 8.623, the retention time of impurity II is 23.194, and the retention time of the unknown impurity is 16.478min); Fig.14 This is the chromatogram of the test sample solution in the destruction test in Test Example 5 (wherein the retention time of nalmefene is 16.025 min, the retention time of impurity II is 21.999 min, and the others are unknown impurities). DETAILED DESCRIPTION

[0018] Example 1 Quality testing method of nalmefene hydrochloride injection of the present invention a. Take the test solution: nalmefene hydrochloride injection (use commercially available nalmefene injection); b. Preparation of control solution: Take 1 ml of the test solution and dilute it to 100 ml with 0.9% sodium chloride; c. Impurity reference substance: Take 2 mg of impurity I and 5 mg of impurity II, dissolve them in the same 100 ml volumetric flask, add 2 / 3 of the total volume of acetonitrile, and dilute with water to the fixed volume; accurately measure 1 ml of the above solution and dilute to 100 ml with 0.9% sodium chloride solution; d. HPLC was used to detect impurities in the test sample. The chromatographic conditions were: The column is Kromasil C18 4.6×250mm, 5μm; Mobile phase A: pH 4.2 (0.02M) sodium dihydrogen phosphate-acetonitrile (97:3) Mobile phase B: acetonitrile-water solution (97:3), gradient elution program: Table 1 Gradient elution conditions Time (min) Mobile phase A% Mobile phase B% 0 90 10 5 90 10 35 70 30 45 70 30 45.1 90 10 55 90 10 ; Mobile phase A: Take 3.12 g of sodium dihydrogen phosphate and 2.0 ml of triethylamine, dilute to 1000 ml with water, adjust pH to 4.2 with phosphoric acid, take 970 ml of buffer, add 30 ml of acetonitrile and mix well.

[0019] Mobile phase B: Take 970 ml of acetonitrile, add 30 ml of water and mix well.

[0020] Flow rate: 1.0 ml / min; The column temperature was 35°C; The injection volume was 20 μl; The detection wavelength is 210 nm.

[0021] Example 2 Investigation of specificity, sensitivity, linearity and repeatability of the detection method of the present invention Blank solution and diluent: water.

[0022] Blank excipient solution: 0.9% sodium chloride solution.

[0023] Nalmefene hydrochloride reference substance stock solution: Take about 5.3 mg of nalmefene hydrochloride reference substance, weigh accurately, place in a 5 ml volumetric flask, add diluent to dissolve and dilute to the scale. (1000 μg / ml) Impurity I reference substance stock solution: Take about 5 mg of impurity I reference substance, weigh accurately, place in a 25 ml volumetric bottle, add diluent to dissolve and dilute to scale, shake well, and the solution is ready. (Contains about 200 μg / ml); Impurity I localization solution: Accurately measure the stock solution of impurity I reference substance, place 0.1ml in a 10ml volumetric bottle, add diluent to dissolve and dilute to the scale, shake well, and the solution is obtained. (Contains about 2μg / ml); Impurity II reference substance stock solution: Take about 5 mg of impurity II reference substance, weigh accurately, place in a 10 ml volumetric bottle, add diluent to dissolve and dilute to scale, shake well, and the solution is ready. (Contains about 500 μg / ml); Impurity I localization solution: Accurately measure the stock solution of impurity I reference substance, place 0.1ml in a 10ml volumetric bottle, add diluent to dissolve and dilute to the scale, shake well, and the solution is obtained. (Contains about 5μg / ml); Quantitative limit solution: Take the impurity I positioning solution, impurity II positioning solution and nalmefene hydrochloride control solution respectively, and continuously dilute them with diluent until the S / N value of each component is about 10, which is the quantitative limit concentration.

[0024] 200% linear solution: accurately measure 1 ml of nalmefene hydrochloride reference substance stock solution, impurity I reference substance stock solution and impurity II reference substance stock solution, place them in the same 10 ml volumetric bottle, add diluent to dilute to the scale, shake well, transfer 1 ml, place them in a 50 ml volumetric bottle, add diluent to dilute to the scale, shake well, and obtain; 150% linear solution: accurately measure 7.5 ml of "200% linear solution" and place it in a 10 ml volumetric bottle. Add diluent to dilute to the mark and shake well. 100% linear solution: accurately measure "5.0 ml of 200% linear solution" and place it in a 10 ml volumetric bottle, add diluent to dilute to the scale, shake well, and the solution is ready; 50% linear solution: accurately measure 2.5 ml of "200% linear solution", place it in a 10 ml volumetric bottle, add diluent to dilute to the scale, shake well, and you have it; 25% linear solution: accurately measure 50% linear solution 5.0ml, place in a 10ml volumetric bottle, add diluent to dilute to the scale, shake well, and obtain; 10% linear solution: Accurately measure "100% linear solution 1.0 ml", place in a 10 ml volumetric flask, add diluent to dilute to the scale, shake well, and obtain.

[0025] Stock solution of impurity spiked test sample: weigh 1 mg of impurity I reference substance and 2.5 mg of impurity II reference substance into the same 50 ml volumetric flask, dissolve in the finished preparation (1 ml: 0.1 mg specification sample), dilute to the scale, and mix well.

[0026] 50% limit solution: Take 0.5ml of the solution and transfer it to a 100ml volumetric flask. Add the finished product to dilute to the mark as the impurity spiked test solution. Prepare 3 copies in parallel.

[0027] 100% limit solution: Take 0.5 ml of the solution and transfer it to a 50 ml volumetric flask. Add the finished product to dilute to the mark as the impurity spiked test solution. Prepare 3 copies in parallel.

[0028] 150% limit solution: Take 0.5 ml of the solution and transfer it to a 25 ml volumetric flask. Add the finished product and dilute to the mark as the impurity spiked test solution. Prepare 3 copies in parallel.

[0029] Test sample spiked solution: Take this product and you'll get it.

[0030] Control solution: Accurately measure 1.0 ml of the test solution, place it in a 100 ml volumetric flask, add blank excipient solution to dilute to the scale, shake well, and obtain.

[0031] Impurity spiked test solution: weigh 1 mg of impurity I reference substance and 2.5 mg of impurity II reference substance into the same 50 ml volumetric flask, dissolve with the finished product of nalmefene hydrochloride injection (1 ml: 0.1 mg specification sample), dilute to the scale, and mix well; take 0.5 ml of the solution, transfer to a 50 ml volumetric flask, add the finished product of nalmefene hydrochloride injection and dilute to the scale as the impurity spiked test solution.

[0032] 1. Exclusivity: Blank solution, blank excipient solution, impurity I positioning solution, impurity II positioning solution, test sample solution, and impurity-spiked test sample solution were injected respectively to examine the method specificity.

[0033] Results: Blank solvent and blank excipients did not interfere with the detection of the main components and impurities of nalmefene hydrochloride. The results of the specificity of known impurities are shown in Table 2. Figure 1 , Figure 2 , Figure 3 .

[0034] Table 2 Specificity test for known impurities

[0035] 2. Limit of Quantitation Limit of Quantitation Results: When the concentration of nalmefene was 0.0195 μg / ml, the S / N of the nalmefene peak in the 6-injection test solution was in the range of 14.2~22.9, which was the quantitative limit concentration; the RSD of the nalmefene peak area in the 6-injection test solution was 8.2%, which was less than 10%; this quantitative limit concentration was equivalent to 2.5% of the limit concentration. The results are shown in Table 3.

[0036] When the concentration of impurity I was 0.0132 μg / ml, the S / N of the nalmefene peak in the 6-injection test solution was in the range of 11.3~17.4, which was its quantitative limit concentration; the RSD of the nalmefene peak area in the 6-injection test solution was 9.5%, which was less than 10%; this quantitative limit concentration was equivalent to 10% of the limit concentration.

[0037] When the concentration of impurity II was 0.0115 μg / ml, the S / N of the nalmefene peak in the 6-injection test solution was in the range of 10.7~24.4, which was its quantitative limit concentration; the RSD of the nalmefene peak area in the 6-injection test solution was 8.2%, which was less than 10%; this quantitative limit concentration was equivalent to 2.5% of the limit concentration.

[0038] Table 3 Statistics of quantitation limit test results

[0039] It can be seen from the quantitative limit results that the quantitative limit concentration of each impurity is no greater than the reporting limit (0.02%), and the relevant substance detection method has a high sensitivity and meets the needs of accurate detection of relevant substance impurities.

[0040] 3. Linear results: Inject linearity solution sample: Linear results: The results are shown in Table 4. Figure 4 , Figure 5 , Figure 6 .

[0041] Table 4 Statistics of linear test results

[0042] Nalmefene has r=1.000 in the concentration range of 0.022μg / ml~1.730μg / ml (equivalent to LOQ concentration~200% limit concentration), which is greater than 0.998; Y%=0.1%, which is less than 25%. It has good linearity in this concentration range and meets the measurement requirements.

[0043] Impurity I has r=0.999 within the concentration range of 0.020μg / ml~0.404μg / ml (equivalent to LOQ concentration~200% limit concentration), which is greater than 0.998; Y%=0.0%, which is less than 25%. It has good linearity within this concentration range and meets the determination requirements.

[0044] Impurity II has r=1.000 in the concentration range of 0.010μg / ml~0.766μg / ml (equivalent to LOQ concentration~200% limit concentration), which is greater than 0.998; Y%=0.1%, which is less than 25%. It has good linearity in this concentration range and meets the determination requirements.

[0045] 4. Repeatability test Repeatability test results: The results are shown in Table 5.

[0046] Table 5 Statistics of repeatability test results

[0047] Impurity I and impurity II were quantitatively added to the test solution. The average content of impurity I in 6 test solutions was 0.15%, with an RSD of 5.7%; the average content of impurity II was 0.31%, with an RSD of 3.0%; and the average content of total impurities was 0.46%, with an RSD of 3.3%.

[0048] 5. Accuracy test Accuracy test results: The results are shown in Table 6.

[0049] Table 6 Statistics of accuracy test results

[0050] The recovery rate was calculated by external standard method. The recovery rates of 9 test solutions were between 94.032% and 102.147%, all within the range of 90.0% to 110.0%. The average recovery rate of 9 test solutions was 98.5%. The RSD of 9 test solutions was 2.6%, less than 10%. The accuracy of impurity I was good and met the needs of accurate determination.

[0051] The recovery rate was calculated using the external standard method. The recovery rates of the 9 test solutions were between 127.645% and 140.210%. The average recovery rate of the 9 test solutions was 133.9%. The RSD of the 9 test solutions was 3.6%, which was less than 10%.

[0052] 6. Stability test Inject impurity I location solution, impurity II location solution, test solution and control solution to examine the solution stability: Stability test results: see Table 7, Table 8.

[0053] Table 7 Results of stability study of reference solution and control solution

[0054] Table 8 Results of stability test of test solution

[0055] The impurity I reference solution was stored at 25℃. Within 25 hours, the peak area recovery was 95.1%~105.3% compared with 0 hour. The solution was stable within 25 hours when stored at 25℃.

[0056] The impurity II reference solution was stored at 25℃. Within 25 hours, the peak area recovery rate was 96.3%~105.2% compared with 0 hour. The solution was stable within 25 hours when stored at 25℃.

[0057] The control solution was stored at 25℃. Within 25 hours, the peak area recovery rate was 99.8%~103.7% compared with that at 0 hours. The solution was stable within 25 hours when stored at 25℃.

[0058] The test solution was stored at 25°C, and the results were calculated by the self-control method at each time point. The absolute difference between the unknown impurity 1 (RRT=0.40) at each time point within 25 hours and the 0h time point was less than 0.01%; the absolute difference between the impurity 2 (RRT=1.40) at each time point within 25 hours and the 0h time point was less than 0.01%; no new impurities exceeding the reporting limit (0.02%) were generated. The test solution was stored at 25°C and the solution was stable within 25 hours.

[0059] Based on the problems existing in the current nalmefene hydrochloride detection method in the 2020 edition of the Chinese Pharmacopoeia, the present invention attempts to change the existing national statutory standard HPLC isocratic elution method to an HPLC gradient elution method to simultaneously detect naltrexone hydrochloride and bisnalmefene in nalmefene hydrochloride. To this end, a series of comparative screening tests were conducted.

[0060] Test Example 1: Testing of Nalmefene Hydrochloride Injection according to the method for testing Nalmefene Hydrochloride in the 2020 edition of the Chinese Pharmacopoeia The test conditions are shown in Table 9.

[0061] Table 9 Chromatographic conditions project content Chromatographic columns Kromasil C18, 4.6×250mm, 5µm Mobile phase Acetonitrile-phosphate buffer (take 7.8g of sodium dihydrogen phosphate, 2ml of triethylamine, add water to 1000ml, and adjust the pH value to 4.2 with 85% phosphoric acid)-acetonitrile (20:80) Elution method Isocratic elution Column temperature (℃) 30 Detection wavelength (nm) 210 Injection volume (μl) System suitability 10μl; other solutions 100μl Sample plate temperature (°C) / Using solution Impurity spike solution In this test example, the solution was prepared as follows: Mobile phase A: acetonitrile-phosphate buffer (take 7.8g of sodium dihydrogen phosphate, 2ml of triethylamine, add water to 1000ml, and adjust the pH value to 4.2 with 85% phosphoric acid)-acetonitrile (20:80) Blank solution and diluent: water.

[0062] Test sample spiked solution: Weigh naltrexone hydrochloride and dinalmefene reference substances to prepare impurity reference substance mother solution; weigh nalmefene hydrochloride API into a volumetric flask, add an appropriate amount of impurity reference substance mother solution to prepare a mixed solution containing nalmefene hydrochloride, naltrexone hydrochloride and dinalmefene at 0.1 mg / ml, 0.2 μg / ml and 0.5 μg / ml respectively.

[0063] Experimental process and results: Although the target peaks appeared normally, the retention time of each peak was short and the naltrexone hydrochloride peak was interfered by other peaks (see Figure 7 ). Among them, 3.544min is the interference peak of impurity I, 3.847min is the peak of impurity I, 11.432min is the peak of impurity II, and 5.738min and 6.064min are unknown impurities.

[0064] Experimental Example 2 Screening test of gradient elution conditions in the detection method of the present invention The inventor intends to use a DAD detector and a Kromasil C18 chromatographic column (4.6×250 mm, 5 μm) for method development. The chromatographic conditions of this experiment are as follows: Chromatographic column: Kromasil C18 4.6×250mm, 5μm; Mobile phase: phosphate buffer as mobile phase A, acetonitrile as mobile phase B; Elution method: gradient elution; Column temperature (°C): 35; Detection wavelength (nm): 210; Injection volume (μl): 20; Sample pan temperature (°C): 8; Test sample concentration (mg / ml): 0.1; Investigation sample: impurity spiked solution.

[0065] Table 10 Gradient elution conditions Time (minutes) Mobile phase A (%) Mobile phase B (%) 0 90 10 5 90 10 35 70 30 77 70 30 82 90 10 92 90 10

[0066] In this test example, the solution was prepared as follows: Mobile phase A: Take 6.8 g of potassium dihydrogen phosphate and 2.0 ml of triethylamine, dilute to 1000 ml with water, and adjust the pH to 4.2 with phosphoric acid.

[0067] Blank solution and diluent: water.

[0068] Test sample spiked solution: Weigh naltrexone hydrochloride and dinalmefene reference substances to prepare impurity reference substance mother solution; weigh nalmefene hydrochloride API into a volumetric flask, add an appropriate amount of impurity reference substance mother solution to prepare a mixed solution containing nalmefene hydrochloride, naltrexone hydrochloride and dinalmefene at 0.1 mg / ml, 0.2 μg / ml and 0.5 μg / ml respectively.

[0069] The experimental process and results are shown in Figure 8 :The separation between target peaks is good and the peaks are normal. However, the overall elution time is too long and the detection efficiency is low. It is not suitable for the detection of multiple batches of small-scale samples and the timely issuance of results.

[0070] Experimental Example 3 Screening test of gradient elution conditions in the detection method of the present invention In order to improve the detection efficiency of the method, the gradient elution time was further optimized based on the above Experimental Example 2. Experimental Example 3 (gradient screening chromatographic conditions) is shown in Table 11, and the gradient is shown in Table 12.

[0071] Table 11 Chromatographic conditions of Experimental Example 3 project content Chromatographic columns Kromasil C18 4.6×250mm, 5μm Mobile phase Mobile phase A was acetonitrile-phosphate buffer; mobile phase B was acetonitrile-water solution Elution method In gradient elution Column temperature (℃) 35 Detection wavelength (nm) 210 Injection volume (μl) 20 Sample plate temperature (°C) 8 Test sample concentration (mg / ml) 0.1 Inspection samples Impurity spike solution Table 12 Gradient elution conditions of Experimental Example 3

[0072] In this test example, the solution was prepared as follows: Mobile phase A: Take 6.8g potassium dihydrogen phosphate and 2.0ml triethylamine, dilute to 1000ml with water, adjust pH to 4.2 with phosphoric acid. Take 970ml buffer, add 30ml acetonitrile and mix well.

[0073] Mobile phase B: Take 970 ml of acetonitrile, add 30 ml of water and mix well.

[0074] Blank solution and diluent: water.

[0075] Test sample spiked solution: Weigh naltrexone hydrochloride and dinalmefene reference substances to prepare impurity reference substance mother solution; weigh nalmefene hydrochloride API into a volumetric flask, add an appropriate amount of impurity reference substance mother solution to prepare a mixed solution containing nalmefene hydrochloride, naltrexone hydrochloride and dinalmefene at 0.1 mg / ml, 0.2 μg / ml and 0.5 μg / ml respectively.

[0076] The experimental process and results are shown in Fig. 9 , Fig.10 , Fig.11 , Fig.12 :① by adding a certain proportion of organic phase and water to the salt phase and the organic phase respectively, the peak retention time drift of the chromatographic system is alleviated; ② the separation between each target peak is good, the peak is normal, the detection time is greatly shortened, and the detection efficiency is improved; ③ by screening the gradient time, the peak parameters such as the separation of known impurities in the spiked test solution are investigated, and the gradient method in the gradient condition 5 is finally selected as the final gradient elution method; ④ in the gradient screening test, when the excessive salt concentration is mixed with acetonitrile, it is very easy to cause salt precipitation to cause the chromatographic column and the liquid chromatography system to be blocked, causing the data to be inaccurate, and the detection efficiency is also greatly limited. Therefore, the present invention further optimizes the durability of this method.

[0077] Test Example 4 Durability Study of the Detection Method of the Present Invention Based on Experiment 3, the salt concentration was further screened to determine the durability of the solution. The chromatographic conditions were as follows: Chromatographic column: Kromasil C18 4.6*250mm 5μm; Mobile phase: Mobile phase A: pH 4.2 (0.02M) sodium dihydrogen phosphate-acetonitrile (97:3), mobile phase B: acetonitrile-water solution (97:3); Column temperature (°C): 35; Detection wavelength (nm): 210; Injection volume (μl): 20; Solution used: impurity spike solution; The gradient elution conditions are shown in Table 13.

[0078] Table 13 Gradient elution conditions Time (min) Mobile phase A% Mobile phase B% 0 90 10 5 90 10 35 70 30 45 70 30 45.1 90 10 55 90 10

[0079] In this test example, the solution was prepared as follows: Mobile phase A: Take 3.12g of sodium dihydrogen phosphate and 2.0ml of triethylamine, dilute to 1000ml with water, adjust pH to 4.2 with phosphoric acid. Take 970ml of buffer, add 30ml of acetonitrile and mix well.

[0080] Mobile phase B: Take 970 ml of acetonitrile, add 30 ml of water and mix well.

[0081] Blank solution and diluent: water.

[0082] Test sample spiked solution: Weigh naltrexone hydrochloride and dinalmefene reference substances to prepare impurity reference substance mother solution; weigh nalmefene hydrochloride API into a volumetric flask, add an appropriate amount of impurity reference substance mother solution to prepare a mixed solution containing nalmefene hydrochloride, naltrexone hydrochloride and dinalmefene at 0.1 mg / ml, 0.2 μg / ml and 0.5 μg / ml respectively.

[0083] The experimental process and results are shown in Fig.13 :After reducing the salt concentration, the problem of poor method durability is solved. When a large amount of samples are injected for a long time, the method is stable, the instrument operates normally, and the method durability is good. This method can be used for method verification.

[0084] Experimental Example 5 Verification of the Interference of Unknown Degradation Impurities in the Detection Method of the Present Invention The following test was conducted using the experimental conditions of Test Example 4: Forced destruction of the test solution: Take 9 ml of nalmefene hydrochloride injection (concentration is 0.1 mg / ml), add 1 ml of 1 mol / L sodium hydroxide solution, and place in a water bath at 80°C.

[0085] The experimental results are shown in Fig.14 :The determined method can accurately detect the possible degradation impurities in the test solution, and the destroyed unknown impurities do not interfere with the determination of the two known impurities. At the same time, the separation between impurities and impurities, and between impurities and main peaks can meet the requirements of accurate determination. This method not only solves the problem of interference with the determination of relevant impurities in the statutory standard, but also further solves the possible interference with the determination of unknown degradation impurities, and has considerable specificity and durability.

Claims

1. A quality detection method for nalmefene hydrochloride injection, characterized in that: It detects impurities in nalmefene hydrochloride injection by HPLC, wherein the impurities include one or a mixture of two or more of impurities I and II, wherein impurity I is naltrexone hydrochloride, and impurity II is bisnalmefene; The chromatographic conditions are: The chromatographic column was: Kromasil C18 4.6×250mm, 5µm; Mobile phase A was acetonitrile-phosphate buffer, mobile phase B was acetonitrile-water solution, and the gradient elution program was: ; Flow rate: 0.9~1.1ml / min; Column temperature is 25~35℃; The injection volume is 20~50μl; The detection wavelength is 205~215nm.

2. The quality detection method of nalmefene hydrochloride injection according to claim 1, characterized in that: The volume ratio of the acetonitrile-phosphate buffer solution is 3:

97. The phosphate buffer solution is prepared by adding 3.12 g of sodium dihydrogen phosphate and 2.0 ml of triethylamine to dilute the mixture to 1000 ml with water and adjusting the pH value to 4.2 with phosphoric acid. The volume ratio of acetonitrile to water in the acetonitrile-water solution is 97:

3.

3. The quality detection method of nalmefene hydrochloride injection according to claim 1, characterized in that: The flow rate is 1.0 ml / min; the column temperature is 35° C.; the injection volume is 20 μl; and the detection wavelength is 210 nm.

4. The quality detection method of nalmefene hydrochloride injection according to any one of claims 1 to 3, characterized in that: It includes the following steps: a. Take the test solution: nalmefene hydrochloride injection; b. Preparation of control solution: Take 1 ml of the test solution and dilute it to 100 ml with 0.9% sodium chloride solution; c. Impurity reference substance: Take 2 mg of impurity I and 5 mg of impurity II, dissolve them in the same 100 ml volumetric flask, add 2 / 3 of the total volume of acetonitrile, and dilute with water to the fixed volume; accurately measure 1 ml of the above solution, add 0.9% sodium chloride solution to dilute to 100 ml, and obtain; d. Use HPLC to detect impurities in the test sample.

5. The quality detection method of nalmefene hydrochloride injection according to claim 4, characterized in that: The retention times of the impurities detected in step d are: impurity I: 6.412 min-8.623 min, impurity II: 22.468-23.546 min; the contents of the impurities are: impurity I: 0.144-0.157% w / w, impurity II: 0.291-0.316% w / w.